LDL Cholesterol Reduction Stocks
Biopharmaceutical innovators in this vertical focus on the development of next-generation lipid-lowering therapies targeting high-risk cardiovascular patients who are refractory to traditional statin regimens.
As of Oct 23, 2026, LDL Cholesterol Reduction has 1 US-listed companies worth $2.4B combined. The median member moved -0.6% over the past week.
Companies in LDL Cholesterol Reduction
- NAMS – NewAmsterdam Pharma Company N.V. Ordinary Shares, $2.4B